Kimberly Martin was recently quoted in Washington Drug Letter's article “Reglan Drugmakers Are Dropped From Generic Label Liability Suit,” released on November 23, 2009. The ruling denied defendants Actavis Elizabeth, Teva Pharmaceuticals USA, Pliva and Barr Pharmaceuticals request for summary judgment and a stay of the proceedings. "The generic manufacturers' argument is that ... failure to warn claims against them are preempted because the FDA regulations applicable to the approval of an ANDA require that the generic label be the same as the branded manufacturer's label. The court in Kellogg found that the claims were not preempted," Kimberly Martin, a litigator and co-chair of the Life Sciences Industry Group at Bradley Arant Boult Cummings, told WDL at the time.